WO1991018602A1 - (+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL - Google Patents
(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL Download PDFInfo
- Publication number
- WO1991018602A1 WO1991018602A1 PCT/US1991/003036 US9103036W WO9118602A1 WO 1991018602 A1 WO1991018602 A1 WO 1991018602A1 US 9103036 W US9103036 W US 9103036W WO 9118602 A1 WO9118602 A1 WO 9118602A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patient
- compound according
- need
- ethyl
- amount
- Prior art date
Links
- 0 CN1CCC(*C2CC(*)(CC3)CC4(CCCCCC4)C3(CC*)CC2)CC1 Chemical compound CN1CCC(*C2CC(*)(CC3)CC4(CCCCCC4)C3(CC*)CC2)CC1 0.000 description 2
- URHGUTQGBYCVMT-UHFFFAOYSA-N Cc1c(C(C2CCNCC2)OC(C(c2ccccc2)OC)=O)cccc1OC Chemical compound Cc1c(C(C2CCNCC2)OC(C(c2ccccc2)OC)=O)cccc1OC URHGUTQGBYCVMT-UHFFFAOYSA-N 0.000 description 2
- WRWPPGUCZBJXKX-UHFFFAOYSA-N Cc(cc1)ccc1F Chemical compound Cc(cc1)ccc1F WRWPPGUCZBJXKX-UHFFFAOYSA-N 0.000 description 1
- URLKBWYHVLBVBO-UHFFFAOYSA-N Cc1ccc(C)cc1 Chemical compound Cc1ccc(C)cc1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention is directed to the compound (+)- ⁇ -(2 ,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4- piperidinemethanol.
- Other aspects of this invention are directed to pharmaceutical compositions containing this compound and the medicinal use of this compound.
- each of Ri, R2, R3, and R 4 is independently selected from hydrogen, halogen, trifluoromethyl, C ⁇ - 6 alkyl, C ⁇ - 6 alkoxy, hydroxy or amino.
- Ri, R2, R3, and R 4 is independently selected from hydrogen, halogen, trifluoromethyl, C ⁇ - 6 alkyl, C ⁇ - 6 alkoxy, hydroxy or amino.
- a new serotonin 5HT 2 antagonist has been discovered which possesses superior in vivo potency.
- This compound is the (+)- isomer of ⁇ -(2,3-dimethoxyphenyl)-l-[2-(4- fluorophenyl)ethyl]-4-piperidinemethanol and the pharmaceutically acceptable salts thereof. It can be described by the following formula:
- (+)- ⁇ -(2,3-dimethoxyphenyl)-1-[2-(4-fluoropheny1)- ethyl]-4-piperidinemethanol is a serotonin 5HT 2 antagonist, it is effective in the treatment of a number of disease states.
- disease states include anxiety, variant angina, anorexia nervosa, Raynaud's phenomenon, intermittent claudication, coronary or peripheral vasospasms, fibromyalgia, cardiac arrhythmias, thrombotic illness and in controling the extrapyramidal symptoms associated with neuroleptic therapy.
- the expression "pharmaceutically acceptable acid addition salts" is intended to apply to any non-toxic organic or inorganic acid addition salt of the base compounds represented by Formula I or any of its intermediates.
- Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric and phosphoric acid and acid metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate.
- Illustrative organic acids which form suitable salts include the mono-, di- and tri-carboxylic acids.
- Illustrative of such acids are, for example, acetic, glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, salicyclic, 2-phenoxybenzoic, p- toluenesulfonic acid and sulfonic acids such as methanesulfonic acid and 2-hydroxyethanesulfonic acid.
- Either the mono- or di-acid salts can be formed, and such salts can exist in either a hydrated or substantially anhydrous form.
- any reference to (+)- ⁇ -(2,3-dimethoxyphenyl)-1-[2-(4- fluorophenyl)ethyl]-4-piperidinemethanol should be construed as encompassing the free base of this compound or an acid addition salt of this compound.
- (+)-isomer of ⁇ -(2,3-dimethoxyphenyl)-l-[2-(4- fluorophenyl)ethyl]-4-piperidinemethanol can be prepared by methods known in the art as was discussed in European Application 0 208 235.
- One suitable method is disclosed below in Reaction Scheme I:
- Step A of Reaction Scheme I an esterification reaction is carried out between racemic ⁇ -(2,3- dimethoxyphenyl)-1-[2-(4-fluoropheny1)ethyl]-4- piperidinemethanol (structure 1) and the (+)-isomer of ⁇ - methoxyphenylacetic acid (structure 2).
- This esterification produces the diastereomeric mixture identifed as structure 3.
- These diastereomers are subjected to silica gel chromatography which separates the two diastereomers, thereby isolating the (+,+) diastereomer as is depicted in Step B.
- Step C the (+,+) diastereomer is hydrolysed which produces the (+)-isomer of ⁇ -(2,3-dimethoxyphenyl)-l- [2-(4-fluoropheny1)ethyl]-4-piperidinemethanol.
- the esterification reaction can be carried out using techniques known in the art. Typically approximately equivalent amounts of racemic ⁇ -(2,3-dimethoxyphenyl)-l-[2- (4-fluorophenyl)ethyl]-4-piperidinemethanol and the (+)- isomer of ⁇ -methoxyphenylacetic acid are contacted in an organic solvent such as methylene chloride, THF, chloroform, toluene and heated to reflux for a period of time ranging from 5 to 24 hours.
- the esterification is typically carried out in the presence of an equivalent amount of dicyclohexylcarbodiimide and a catalytic amount of 4- dimethylaminopyridine.
- the resulting diastereomers can be isolated by filtration of the dicyclohexylurea and evaporation of the filtrate.
- the diastereomers are then subjected to silica gel chromatograpy which separates the (+,+) and the (-,+) diastereomers.
- This chromatagraphic separation may be carried out as is known in the art.
- a 1:1 mixture of hexane and ethyl acetate is one suitable eluent.
- the resulting (+,+) diastereomer is then subjected to a hydrolysis reaction which produces the (+)-isomer of ⁇ -(2,3- dimethoxyphenyl)-1-[2-(4-fluoropheny1)ethyl]-4-piperidine ⁇ methanol.
- the hydrolysis is carried out by contacting the diastereomer with an excess of a base such as potassium carbonate in an aqueous alcoholic solution.
- the hydrolysis is carried out at a temperature of about 15 to 30°C for a period of time ranging from 2 to 24 hours.
- (+)-isomer of ⁇ -(2,3-dimethoxyphenyl)-l-[2-(4- fluorophenyl)ethyl]-4-piperidinemethanol may then be recovered by dilution with water and extraction with methylene chloride. It is then purifed by recrystallization from a solvent system such as cyclohexane/hexane or ethyl acetate/hexane.
- This compound is contacted with Mg thereby forming a Grignard Reagent which is then reacted with 2,3-dimethoxybenzaldehyde which produces the desired product ( ⁇ )- ⁇ -(2,3-dimethoxyphenyl)-!-[2-(4- fluorophenyl)ethyl]-4-piperidinemethanol.
- the (+)-isomer of ⁇ -methoxyphenylacetic acid is known in the art.
- (+)- isomer of ⁇ -(2,3-dimethoxyphenyl)-l-[2-(4- fluorophenyl)ethyl]-4-piperidinemethanol possesses superior in vivo potency when compared with the other compounds encompassed by the European Application described above, EP 208 235.
- mice typically produces a characteristic head twitch in the mice.
- the mice are administered 5-MeO-DMT and a test compound.
- An absence of head twitches in the mice is considered to be predictive of the ability of the test compound to antagonize the 5HT 2 receptor in ⁇ i ⁇ o .
- Table I reports the ED 50 of (+)- ⁇ -(2,3-dimethoxyphenyl)- 1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol (Invention). For comparative purposes, it also reports the ED50 of ⁇ -phenyl-l-(2-phenylethyl)-4-piperidinemethanol (Compound B) as its racemate and as its (+)-isomer and ⁇ - (2,3-dimethoxyphenyl)-1-(2-phenylethyl)-4-piperidinemethanol (Compound C) . These compounds were identified as being the most preferred species of the EPO 208 235 application. The European applicaton does not specify which isomer of these compounds is preferred.
- the dosage range at which (+)- ⁇ -(2,3-dimethoxyphenyl)-1- [2-(4-fluorophenyl)ethyl]-4-piperidinemethanol exhibits its ability to block the effects of serotonin at the 5HT 2 receptor can vary depending upon the particular disease or condition being treated and its severity, the patient, other underlying disease states the patient is suffering from, and other medications that may be concurrently administered to the patient. Generally though, this compound will exhibit its serotonin 5HT 2 antagonist properties at a dosage range of from about 0.001 mg/kg of patient body weight/day to about 100.0 mg/kg of patient body weight/day.
- the compound is typically administered from 1-4 times daily. Alternatively, it can be administered by continuous infusion.
- the compounds can be administered orally or parenterally to achieve these effects.
- the compound is a serotonin 5HT 2 antagonist, it is useful in the treatment of a variety of disease states and conditions. It is useful in the treatment of anxiety, variant angina, stable angina, anorexia nervosa, Raynaud's phenomenon, intermittent claudication and coronary or peripheral vasospasms. These conditions and diseases can be relieved by administering to a patient in need thereof of, (+)- ⁇ -(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4- piperidinemethanol, in an amount sufficient to treat the disease or condition (i.e. an anxiolytic amount, anti- anginal amount, anti-anorexic amount, etc.). This quantity will be within the dosage range at which the compound exhibits its serotonin 5HT 2 antagonistic properties.
- fibromyalgia refers to a chronic disease state wherein the patient suffers from numerous symptoms such as, for example, widespread generalized musculoskeletal pains, aching, fatigue, morning stiffness and a sleep disturbance which can be characterized as an inadequacy of stage 4 sleep.
- an anti-fibromyalgia amount relieves or alleviates the symptoms the patient is experiencing.
- An anti-fibromyalgia amount will be within the dosage range described above wherein this compound exhibits its serotonin 5HT 2 antagonist effect.
- This compound can also be used to treat the extrapyramidal symptoms that often accompany the administration of neuroleptic agents such as haloperidol, chlorpromazine, etc.
- EPS extrapyramidal side effects
- Some patients experience a parkinsonian-like syndrome, wherein they experience muscular rigidity and tremors. Others experience akathisia, which can be characterized as a compelling need for the patient to be in constant movement.
- a few patients experience acute dystonic reactions, such as facial grimacing and torticollis.
- the administration of this compound to a patient in need thereof, in an anti-EPS amount will relieve or alleviate the symptoms that the patient is experiencing.
- the amount of compound which produces this anti-EPS effect is an amount within the dosage range at which this compound exhibits its serotonin 5H ⁇ 2 antagonistic effect.
- the term "patient” refers to a warm-blooded animal, such as for example rats, mice, dogs, cats, guinea pigs, and primates such as humans, and;
- the term "treat” refers to either relieving or alleviating the patient's disease or condition.
- (+)- ⁇ -(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]- 4-piperidinemethanol also possess antiarrhythmic properties. It increases the duration of the action potential of myocardial tissue producing an increase in the refractory period of that tissue. Thus, under the classification system of Vaughan Williams, this compound exhibits a Class III antiarrhythmic activity. Since the compound is a Class III antiarrhythmic, it will be useful for treating a variety of arrhythmic conditions of the heart.
- arrhythmic conditions which are amendable to treatment with the compounds of the present invention include supra ventricular arrhythmias such as atrial tachycardia, atrial flutter, atrial fibrillation, and life threatening ventricular arrhythmias such as ventricular tachycardia, or ventricular fibrillation. This compound will also prevent recurrent episodes of the arrhythmias mentioned above.
- the quantity of compound needed to either terminate an arrhythmic episode or prevent the occurrence of an arrhythmic episode will vary depending upon the route of administration, the patient, the severity of the patient's condition, and the presence of other underlying disease states. However as a general guideline, if the compound is being administered orally, then it is preferably administered within a dosage range of from about 1.0 to about 400 mg/kg of patient body weight/day. Likewise, if the compound is being administered parenterally then it is preferably administered within a dosage range of from about 0.1 to about 100 mg/kg of patient body weight/day.
- the patient's response to the compound can be monitored via an EKG or any other technique conventionally used in the art.
- arrhythmia refers to any variation from the normal rhythm of the heart beat, and
- antiarrhythmic refers to a compound capable of either preventing or alleviating an arrhythmia.
- (+)- ⁇ -(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]- 4-piperidinemethanol is also useful in the treatment of thrombotic illness.
- a thrombus is an aggregation of blood factors, primarily platelets and fibrin with entrapment of other formed elements of the blood.
- Thrombi can also consist of primarily platelet aggregates. Thrombi are typically formed in order to prevent excessive bleeding from injured blood vessels. Thrombi are typically formed in the following manner.
- the vascular endothelium serves as a barrier between the blood-borne platelets which continually circulate throughout the body and the proaggregatory subendothelial components, which are primarily collagen.
- the cell membranes of the endothelial lining contain negatively charged components which serve to create an electrostatic repulsion between the platelets and the lining of the vessels. Trauma to the blood vessel will disrupt this endothelial lining and allow the platelets to come in contact with the underlying collagen and fibronectin. This causes the platelets to adhere to the subendothelial surface.
- This initial adherence causes the release, from these platelets, of a number of chemicals such as adenosine diphosphate, serotonin, and thromboxane A 2 , all of which have a proaggregatory effect upon the initial platelet aggregate or plug and stimulate other circulating platelets to adhere to this newly formed plug.
- the additional adherence of these platelets stimulate the further release of these proaggregatory chemicals, which causes further growth of the platelet plug.
- a self- perpetuating cycle is initiated which promotes the growth of the plug.
- activated platelets accelerate the generation of thrombin which acts to convert the plasma protein, fibrinogen, into fibrin, thereby stabilizing the thrombus and promoting its growth.
- thrombin Prior to the conversion of fibrinogen into fibrin, a sequence of enzymatic conversions take place on the platelet surface which ultimately leads to the formation of fibrin. Both the negatively charged phospholipids on the platelet surface and calcium are essential for the maximal activation of Factor X. Once Factor X is activated, prothrombin is converted to thrombin which cleaves fibrinogen into fibrin and activates Factor XIII. This Factor catalyzes the crosslinking reaction of fibrin which stabilizes the platelet mass. In addition, thrombin is a powerful platelet activator and will act to perpetuate the process.
- a reaction is initiated in which a number of positive feedback control systems act to produce a thrombus which blocks off the affected vasculature.
- the entire process ie. platelet aggregation, fibrin generation, and polymerization
- hemostasis is important in the prevention of excessive bleeding from the wound.
- thrombi Although the formation of thrombi is desirable in a bleeding vessel, it is pathological in an intact vessel. Thrombi occur in intact vessels due to minor alterations in the endothelial cell surface or injuries that result in the disruption of the endothelial linings. Even relatively minor alterations can allow the platelets to come in contact with collagen and initiate the process described above. These minor alterations occur from a variety of causes. These causes include stasis, (ie. decreased movement of blood in the cardiac chambers or blood vessels) which induces damage due to lack of oxygen and reduces the shear forces that ordinarily discourage platelet interaction. Another cause is the damage which the process of atherosclersis inflicts upon the endothelial linings.
- Endothelial linings are known to be disrupted at the site of atherosclerotic lesion.
- Ketanserin is a serotonin antagonist. It reacts at the 5HT 2 receptor. Bush et al. reported this compound was extremely effective in preventing thrombus formation in canine models which have been designed to screen for this activity. Drug Development Research, Vol. 7, pages 319-340 (1986).
- (+)- ⁇ -(2,3-dimethoxyphenyl)- 1-f2-(4-fluorophenyl)ethyl]-4-piperidinemethanol is also effective in the prevention of acute thrombosis, especially those of the coronary arteries.
- This compound decreases the rate at which platelets aggregate as the result of minor alterations in the endothelial lining of the vasculature and therefore prevent the formation of acute pathological thrombi.
- the compound Since the compound is effective as an antithrombotic agent, it can be utilized in a variety of clinical settings in which a patient is at risk of developing pathological acute thrombi. As noted above, it should be administered on a prophylactic basis to prevent the occurrence of an acute thrombotic episode, not to lyse thrombi which have already occurred.
- patients who have undergone thrombolysis with agents such as tissue plasminogen activator are at a high risk of suffering subsequent acute coronary artery thrombosis.
- This compound can be administered to these patients to prevent them from suffering additional acute coronary artery thrombotic episodes and any ensuing myocardial infarction.
- TIA transient ischemic attacks
- the compound can be used to prevent the occurrence of pathological acute thrombotic or embolic episodes.
- the compound be administered to the patient in an antithrombotic quantity.
- the dosage range at which this compound exhibits this antithrombotic effect can vary depending upon the severity of the thrombotic episode, the patient, other underlying disease states the patient is suffering from, and other medications that may be concurrently administered to the patient.
- this compound will exhibit an antithrombotic effect at a dosage range of from about 0.001 mg/kg of patient body weight/day to about 100 mg/kg of patient body weight/day.
- the administration schedule will also vary widely, but will typically be from 1 to 4 times daily. This compound can be administered by a variety of routes. It is effective if administered orally or parenterally.
- the compound can be administered in combination with other antiaggretory substances, such as, for example, aspirin (300-1200mg/day) , dipyridamole (300-400 mg/day), ticlopidine (50-500mg/day) , warfarin (25-300 mg/day), hirudin (0.1-100 mg/kg/day), or MDL 28,050.
- the compound can also be administered in combination with a thromboxane synthetase inhibitor, suclr as, for example, ozagrel, dazmegrel, SQ 29,548, or SQ 30,741.
- thromboxane synthetase inhibitors are typically administered at a dosage range of from 0.5-50mg/kg/day.
- the compound and the thromboxane synthetase inhibitors can be compounded into a single dosage form and administered as combination product. Methods for producing such dosage forms are well known in the art.
- antithrombotic should be construed as referring to the ability to either prevent or decrease the formation of acute pathological thrombi or emboli. It should not be construed as referring to the ability to dissolve a thrombus that has already formed.
- embolus can be an entire thrombus or a portion of a thrombus, that produces occlusion by moving to the site of occlusion from other parts of the circulation. It is not produced at the site of occlusion as is a thrombus.
- the compound can be formulated into pharmaceutical dosage forms using techniques well known in the art.
- the compound can be formulated into solid or liquid preparations such as capsules, pills, tablets, lozenges, melts, powders, suspensions, or emulsions.
- Solid unit dosage forms can be capsules of the ordinary gelatin type containing, for example, surfactants, lubricants and inert fillers such as lactose, sucrose, and cornstarch or they can be sustained release preparations.
- the compound in another embodiment, can be tableted with conventional tablet bases such as lactose, sucrose, and cornstarch in combination with binders, such as acacia, cornstarch, or gelatin, disintegrating agents such as potato starch or algenic acid, and a lubricant such as stearic acid or magnesium stearate.
- binders such as acacia, cornstarch, or gelatin
- disintegrating agents such as potato starch or algenic acid
- a lubricant such as stearic acid or magnesium stearate.
- Liquid preparations are prepared by dissolving the active ingredient in an aqueous or non- aqueous pharmaceutically acceptable solvent which may also contain suspending agents, sweetening agents, flavoring agents, and preservative agents as are known in the art.
- the compound or its salts may be dissolved in a physiologically acceptable pharmaceutical carrier and administered as either a solution or a suspension.
- suitable pharmaceutical carriers are water, saline, dextrose solutions, fructose solutions, ethanol, or oils of animal, vegetative, or synthetic origin.
- the pharmaceutical carrier may also contain preservatives, buffers, etc. as are known in the art.
- the compound may be admixed with any inert carrier and utilized in laboratory assays in order to determine the concentration of the compounds within the urine, serum, etc. of the patient as is known in the art.
- Example 1 demonstrates the preparation of the starting material ( ⁇ )- ⁇ -(2,3-dimethoxyphenyl)-l-[2-(4- fluorophenyl)ethyl]-4-piperidinemethanol, structure 1.
- Example 2 demonstrate an alternative manner of preparing ( ⁇ )- ⁇ -(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol, structure 1.
- n-Butyl lithium (14.5 mL of a 2.5 M solution in hexane, 36.3 mmol) was added via syringe to a stirred solution of veratrole (5.00 g, 36.2 mmol) in THF (50 mL, anhydrous) under argon at 0°C. The ice bath was removed and the mixture was allowed to stir for 90 minutes. The mixture was cooled to -78°C and treated with 4-(N-methoxy-N-methylcarboxamido)-l- piperidinecarboxylic acid 1,1-dimethylethyl ester (9.20 g, 33.8 mmol) in THF (50 mL, anhydrous) via syringe.
- 1,1-dimethylethyl ester (7.75 g, 22.2 mmol) was dissolved in trifluoroacetic acid (50 mL, 650 mmol) and stirred for 45 minutes. The entire solution was poured into ether (900 mL) and allowed to stand overnight. Filtration yielded 4-(2,3- dimethoxyphenyl)-4-piperidinylmethanone trifluoroacetate as fine white needles, m.p. 123°C. Anal. Calcd for Ci 4 Hi 9 N ⁇ 3 'CF 3 C0 2 H: C, 52.89; H, 5.55; N, 3.86. Found: C, 52.77; H, 5.62; N, 3.82.
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP91910548A EP0531410B1 (en) | 1990-06-01 | 1991-04-30 | (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinemethanol |
DE69105501T DE69105501T2 (en) | 1990-06-01 | 1991-04-30 | (+) - ALPHA- (2,3 DIMETHOXYPHENYL) -1- [2- (FLUOROPHENYL) ETHYL] -4-PIPERIDINE METHANOL. |
AU79509/91A AU652759B2 (en) | 1990-06-01 | 1991-04-30 | (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)- 4-piperidinemethanol |
FI925342A FI95370C (en) | 1990-06-01 | 1992-11-25 | Process for the preparation of therapeutically active (+) - - (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-piperidinemethanol |
NO924619A NO179250C (en) | 1990-06-01 | 1992-11-30 | Analogous Process for Preparation of Therapeutically Active (+) - (2,3-Dimethoxyphenyl) -1- [2- (4-Fluorophenyl) Ethyl α-4-Piperidinemethanol |
GR950400305T GR3015087T3 (en) | 1990-06-01 | 1995-02-16 | (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(fluorophenyl)ethyl]-4-piperidinemethanol. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53195490A | 1990-06-01 | 1990-06-01 | |
US531,954 | 1990-06-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991018602A1 true WO1991018602A1 (en) | 1991-12-12 |
Family
ID=24119769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1991/003036 WO1991018602A1 (en) | 1990-06-01 | 1991-04-30 | (+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL |
Country Status (15)
Country | Link |
---|---|
US (6) | US5134149A (en) |
EP (1) | EP0531410B1 (en) |
JP (1) | JP2869512B2 (en) |
KR (1) | KR100211713B1 (en) |
AT (1) | ATE114467T1 (en) |
AU (1) | AU652759B2 (en) |
CA (1) | CA2083698C (en) |
DE (1) | DE69105501T2 (en) |
DK (1) | DK0531410T3 (en) |
ES (1) | ES2067937T3 (en) |
FI (1) | FI95370C (en) |
GR (1) | GR3015087T3 (en) |
HU (1) | HU213271B (en) |
NO (1) | NO179250C (en) |
WO (1) | WO1991018602A1 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0796619A1 (en) * | 1996-03-21 | 1997-09-24 | Merrell Pharmaceuticals Inc. | Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders |
WO1999011641A1 (en) * | 1997-09-03 | 1999-03-11 | Merck Sharp & Dohme Limited | Phenylindole derivatives as 5-ht2a receptor antagonists |
WO2000012090A1 (en) * | 1998-08-28 | 2000-03-09 | Aventis Pharmaceuticals Inc. | THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS |
WO2000035423A1 (en) * | 1998-12-16 | 2000-06-22 | Aventis Pharmaceuticals Inc. | Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same |
WO2000037068A1 (en) * | 1998-12-22 | 2000-06-29 | Sanofi-Synthelabo | Use of a 5ht2a and 5ht2a/c receptor antagonist for preparing medicines for treating snoring and high resistance syndrome of upper anatomical airways |
EP1113015A1 (en) * | 1999-12-29 | 2001-07-04 | Pfizer Products Inc. | Optically active 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists |
US6455526B1 (en) * | 1998-12-16 | 2002-09-24 | Aventis Pharmaceuticals, Inc. | Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same |
US6479480B1 (en) | 1998-07-24 | 2002-11-12 | Merck Sharp & Dohme Ltd. | Phenylindole derivatives as 5-ht2a receptor ligands |
US6486153B1 (en) | 1997-09-04 | 2002-11-26 | Merck Sharp & Dohme Ltd. | Phenylindole derivatives as 5-HT2A receptor ligands |
US6559166B1 (en) | 1999-01-19 | 2003-05-06 | Merck Sharp & Dohme Ltd. | Phenylsulphonyl derivatives as 5-HT receptor ligands |
US6713627B2 (en) | 1998-03-13 | 2004-03-30 | Aventis Pharmaceuticals Inc. | Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
US6756370B1 (en) | 1999-08-21 | 2004-06-29 | Merck Patent Gmbh | Piperidine alcohols |
US6852718B2 (en) | 2000-03-31 | 2005-02-08 | Merck Sharp & Dohme Ltd | Phenylsulphonylipiperazinyl derivatives as 5-HT receptor ligands |
WO2006029182A2 (en) * | 2004-09-07 | 2006-03-16 | The La Jolla Institute For Molecular Medicine | Use of mdl-100,907 for treatment of allergic and eosinophil mediated diseases |
KR100737718B1 (en) * | 1999-07-16 | 2007-07-11 | 아벤티스 파마슈티칼스 인크. | Sulfuric acid mono-[3-?1-[2-4-fluoro-phenyl-ethyl]-piperidin-4-yl?-hydroxy-methyl-2-methoxy-phenyl]ester and pharmaceutical composition comprising the same |
US7345096B2 (en) | 2002-10-15 | 2008-03-18 | Wyeth | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
US7365076B2 (en) | 2003-10-14 | 2008-04-29 | Wyeth | Substituted aryl cycloalkanol derivatives and methods of their use |
US7402698B2 (en) | 2003-10-14 | 2008-07-22 | Wyeth | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use |
US7414052B2 (en) | 2004-03-30 | 2008-08-19 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
US7419980B2 (en) | 2003-10-14 | 2008-09-02 | Wyeth | Fused-aryl and heteroaryl derivatives and methods of their use |
US7491723B2 (en) | 2003-10-14 | 2009-02-17 | Wyeth | Alkanol and cycloalkanol-amine derivatives and methods of their use |
US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
US7524846B2 (en) | 2003-10-14 | 2009-04-28 | Wyeth | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use |
US7531543B2 (en) | 2003-10-14 | 2009-05-12 | Wyeth | Phenylpiperazine cycloalkanol derivatives and methods of their use |
US7550485B2 (en) | 2003-10-14 | 2009-06-23 | Wyeth | Substituted N-heterocycle derivatives and methods of their use |
WO2009152647A1 (en) * | 2008-06-20 | 2009-12-23 | 江苏恩华药业股份有限公司 | Aralkyl piperidine derivatives and their uses as antalgic or ataractic agent |
EP2301625A2 (en) | 2004-09-30 | 2011-03-30 | F. Hoffmann-La Roche AG | Compositions and methods for treating cognitive disorders |
EP2343073A2 (en) | 2003-12-11 | 2011-07-13 | Sepracor Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE114467T1 (en) * | 1990-06-01 | 1994-12-15 | Merrell Dow Pharma | (+)-ALPHA-(2,3 DIMETHOXYPHENYL)-1-(2-(FLUOROPHENYL)ETHYL>-4-PIPERIDINEMETHANOL. |
US6004980A (en) * | 1990-06-01 | 1999-12-21 | Merrell Pharmaceuticals, Inc. | (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
US6028083A (en) * | 1997-07-25 | 2000-02-22 | Hoechst Marion Roussel, Inc. | Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol |
KR100258018B1 (en) * | 1997-12-23 | 2000-07-01 | 유승필 | A pharmaceutical composition comprising ticlopidine and ginkgo extract |
US20050261341A1 (en) * | 1998-03-13 | 2005-11-24 | Aventis Pharmaceuticals Inc. | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
TWI249526B (en) * | 1998-03-13 | 2006-02-21 | Aventis Pharma Inc | Novel processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
SE9801516D0 (en) * | 1998-04-30 | 1998-04-30 | Maria Carlsson | M100907 / 4-Piperidine methanol derivatives for autism |
US6939879B2 (en) * | 1998-08-28 | 2005-09-06 | Aventis Pharmaceuticals Inc. | Use of R (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of substance induced insomnia |
US6277864B1 (en) | 1998-08-28 | 2001-08-21 | Aventis Pharmaceuticals Inc. | Use of R- +)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders |
UA57859C2 (en) * | 1998-10-14 | 2003-07-15 | Авентіс Фармасьютікалз Інк. | esters of (+)-<sub>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-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol, a method for preparation thereof, a pharmaceutical composition, a method for inhibition of SEROTONIN EFFECT on 5HT</sub><sub>2A receptor, a method for treatment |
US6465490B1 (en) | 1999-07-16 | 2002-10-15 | Aventis Pharmaceuticals Inc. | Sulfuric acid mono-[3({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester |
DK1260512T3 (en) * | 2000-02-29 | 2007-11-05 | Mitsubishi Pharma Corp | Hitherto unknown cyclic amide derivatives |
US20020099076A1 (en) * | 2000-05-25 | 2002-07-25 | Richard Scheyer D. | Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis |
US20030177248A1 (en) * | 2001-09-05 | 2003-09-18 | International Business Machines Corporation | Apparatus and method for providing access rights information on computer accessible content |
KR20050025628A (en) * | 2002-07-19 | 2005-03-14 | 바이오비트럼 에이비 | Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders |
RU2340333C2 (en) * | 2002-08-15 | 2008-12-10 | Вайет | Agonism of 5нт2a-receptor for treatment of disturbance of thermoregulation function |
US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
CA2834920A1 (en) | 2011-05-23 | 2012-11-29 | Sanofi | Process for the preparation of deuterated compounds containing n-alkyl groups |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2833775A (en) * | 1951-08-17 | 1958-05-06 | Schering Corp | Substituted piperidines |
US3655676A (en) * | 1970-11-19 | 1972-04-11 | Smith Kline French Lab | 4-hydroxy-3-hydroxymethylphenyl-2-piperidinylcarbinols |
GB1316424A (en) * | 1969-05-20 | 1973-05-09 | Minnesota 3M Lab Ltd | Alpha-hydroxy-substituted-phenyl-alpha-2-piperidyl-methanols and process for the preparation thereof |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3058979A (en) * | 1957-05-13 | 1962-10-16 | Smith Kline French Lab | New perfluoroalkylphenothiazine derivatives |
US3394131A (en) * | 1961-04-26 | 1968-07-23 | Squibb & Sons Inc | Acid esters of phenothiazine |
US3194733A (en) * | 1961-04-26 | 1965-07-13 | Olin Mathicson Chemical Corp | Phenothiazine compositions and method of treating mental disorders |
US4701461A (en) * | 1983-03-21 | 1987-10-20 | Usv Pharmaceutical Corporation | Substituted cyclic amines |
US4569941A (en) * | 1983-03-21 | 1986-02-11 | Usv Pharmaceutical Corp. | Method of using phenyl-alkylene-2-pyridyl derivatives to increase cardiac contractility in a mammal |
US4623728A (en) * | 1984-07-26 | 1986-11-18 | Pfizer Inc. | Intermediates for 1,3-disubstituted piperidine compounds as neuroleptic agents |
US4632929A (en) * | 1985-01-17 | 1986-12-30 | Usv Pharmaceutical Corp. | Method of hypertensive treatment using phenyl-alkylene-2-pyridyl derivatives |
US4804663A (en) * | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
US4912117A (en) * | 1985-07-02 | 1990-03-27 | Merrell Dow Pharmaceuticals Inc. | Novel chemical compounds |
US5169096A (en) * | 1985-07-02 | 1992-12-08 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl-piperidine-methanol derivatives |
US4783471A (en) * | 1985-07-02 | 1988-11-08 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl piperidine methanol derivatives and the uses thereof |
US5021428A (en) * | 1985-07-02 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Novel chemical compounds for the prophylactic treatment of migraine |
ZA864772B (en) * | 1985-07-02 | 1987-02-25 | Merrell Dow Pharma | Novel chemical compounds |
US4762842A (en) * | 1985-10-01 | 1988-08-09 | Eli Lilly And Company | Selective method for blocking 5HT2 receptors |
IT1205685B (en) * | 1987-05-26 | 1989-03-31 | Erregierre Spa | PROCESS FOR THE PREPARATION OF ALPHA- (ALCHYLPHENYL) -4- (HYDROXY DIPHENYLMETHYL) -1-PIPERIDINE BUTANOL |
FI95572C (en) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt |
ZA888572B (en) * | 1987-11-23 | 1989-08-30 | Merrell Dow Pharma | Treatment of fibromyalgia |
US4877798A (en) * | 1987-11-23 | 1989-10-31 | Merrell Dow Pharmaceuticals Inc. | Treatment of fibromyalgia |
JPH02138214A (en) * | 1987-12-10 | 1990-05-28 | Merrell Dow Pharmaceut Inc | Therapeutic method of anxiety |
US5093341A (en) * | 1987-12-17 | 1992-03-03 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl piperidine derivatives useful as antithrombolytic agents |
US5064838A (en) * | 1988-01-21 | 1991-11-12 | Merrell Dow Pharmaceuticals | 1,4-disubstituted-piperidinyl compounds as pain relievers |
DE3888340T2 (en) * | 1988-01-21 | 1994-06-30 | Merrell Dow Pharma | Use of 1,4-disubstituted-piperidinyl compounds for the manufacture of a medicament for the treatment of insomnia. |
KR890012971A (en) * | 1988-02-10 | 1989-09-20 | 원본미기재 | N-substituted-arylalkyl and arylalkylene aminoheterocyclic compounds as cardiovascular antihistamines and secretory inhibitors |
US4921863A (en) * | 1988-02-17 | 1990-05-01 | Eisai Co., Ltd. | Cyclic amine derivatives |
AU629534B2 (en) * | 1988-02-24 | 1992-10-08 | A.H. Robins Company, Incorporated | New methods and related compounds |
ZA891901B (en) * | 1988-03-17 | 1989-11-29 | Merrell Dow Pharma | Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy |
US5158952A (en) * | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
US5254556A (en) * | 1988-11-07 | 1993-10-19 | Janssen Pharmaceutica N.V. | 3-piperidinyl-1,2-benzisoxazoles |
US5070087A (en) * | 1989-05-08 | 1991-12-03 | A. H. Robins Company, Incorporated | Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents |
US5106855A (en) * | 1989-12-20 | 1992-04-21 | Merrell Dow Pharmaceuticals Inc. | Method for the treatment of glaucoma |
US5116846A (en) * | 1990-03-28 | 1992-05-26 | Du Pont Merck Pharmaceutical Company | N-aralkyl piperidine derivatives as psychotropic drugs |
ATE114467T1 (en) * | 1990-06-01 | 1994-12-15 | Merrell Dow Pharma | (+)-ALPHA-(2,3 DIMETHOXYPHENYL)-1-(2-(FLUOROPHENYL)ETHYL>-4-PIPERIDINEMETHANOL. |
EP0661266A1 (en) * | 1993-12-27 | 1995-07-05 | Toa Eiyo Ltd. | Substituted cyclic amine compounds as 5HT2 antagonists |
US5618824A (en) * | 1994-03-09 | 1997-04-08 | Merrell Pharmaceuticals Inc. | Treatment of obsessive-compulsive disorders with 5-HT2 antagonists |
IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
-
1991
- 1991-04-30 AT AT91910548T patent/ATE114467T1/en not_active IP Right Cessation
- 1991-04-30 JP JP3510161A patent/JP2869512B2/en not_active Expired - Lifetime
- 1991-04-30 WO PCT/US1991/003036 patent/WO1991018602A1/en active IP Right Grant
- 1991-04-30 KR KR1019920703050A patent/KR100211713B1/en not_active IP Right Cessation
- 1991-04-30 DK DK91910548.6T patent/DK0531410T3/en active
- 1991-04-30 HU HU9203779A patent/HU213271B/en unknown
- 1991-04-30 AU AU79509/91A patent/AU652759B2/en not_active Expired
- 1991-04-30 EP EP91910548A patent/EP0531410B1/en not_active Expired - Lifetime
- 1991-04-30 DE DE69105501T patent/DE69105501T2/en not_active Expired - Lifetime
- 1991-04-30 ES ES91910548T patent/ES2067937T3/en not_active Expired - Lifetime
- 1991-04-30 CA CA002083698A patent/CA2083698C/en not_active Expired - Lifetime
- 1991-07-26 US US07/736,194 patent/US5134149A/en not_active Expired - Lifetime
-
1992
- 1992-11-25 FI FI925342A patent/FI95370C/en active
- 1992-11-30 NO NO924619A patent/NO179250C/en not_active IP Right Cessation
-
1995
- 1995-01-13 US US08/372,694 patent/US5561144A/en not_active Expired - Lifetime
- 1995-02-16 GR GR950400305T patent/GR3015087T3/en unknown
- 1995-06-07 US US08/485,700 patent/US5700813A/en not_active Expired - Lifetime
- 1995-06-07 US US08/485,701 patent/US5700812A/en not_active Expired - Lifetime
- 1995-06-07 US US08/476,538 patent/US5721249A/en not_active Expired - Lifetime
-
1997
- 1997-10-02 US US08/942,629 patent/US5874445A/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2833775A (en) * | 1951-08-17 | 1958-05-06 | Schering Corp | Substituted piperidines |
GB1316424A (en) * | 1969-05-20 | 1973-05-09 | Minnesota 3M Lab Ltd | Alpha-hydroxy-substituted-phenyl-alpha-2-piperidyl-methanols and process for the preparation thereof |
US3655676A (en) * | 1970-11-19 | 1972-04-11 | Smith Kline French Lab | 4-hydroxy-3-hydroxymethylphenyl-2-piperidinylcarbinols |
Non-Patent Citations (1)
Title |
---|
See also references of EP0531410A4 * |
Cited By (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997034603A1 (en) * | 1996-03-21 | 1997-09-25 | Hoechst Marion Roussel, Inc. | USE OF (+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL IN TREATING DEPRESSIVE DISORDERS AND BIPOLAR DISORDERS |
US6022877A (en) * | 1996-03-21 | 2000-02-08 | Hoechst Marion Roussel, Inc. | Use of (+)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl)ethyl]-4-piperidin emethanol in treating depressive disorders and bipolar disorders |
EP0796619A1 (en) * | 1996-03-21 | 1997-09-24 | Merrell Pharmaceuticals Inc. | Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders |
CN1114406C (en) * | 1996-03-21 | 2003-07-16 | 阿温蒂斯药物公司 | Use of (+)-'alpha'-(2,3-dimethyoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol in treating depressive disorders and bipolar disorders |
US6380216B1 (en) | 1996-03-21 | 2002-04-30 | Aventis Pharmaceuticals Inc. | Use of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol in treating depressive disorders and bipolar disorders |
US6316468B1 (en) | 1997-09-03 | 2001-11-13 | Merck Sharp & Dohme Ltd. | Phenylindole derivatives as 5-HT2A receptor antagonists |
WO1999011641A1 (en) * | 1997-09-03 | 1999-03-11 | Merck Sharp & Dohme Limited | Phenylindole derivatives as 5-ht2a receptor antagonists |
US6486153B1 (en) | 1997-09-04 | 2002-11-26 | Merck Sharp & Dohme Ltd. | Phenylindole derivatives as 5-HT2A receptor ligands |
US6713627B2 (en) | 1998-03-13 | 2004-03-30 | Aventis Pharmaceuticals Inc. | Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
US7332607B2 (en) | 1998-03-13 | 2008-02-19 | Aventis Holdings Inc. | Processes for the preparation of (R)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
US6479480B1 (en) | 1998-07-24 | 2002-11-12 | Merck Sharp & Dohme Ltd. | Phenylindole derivatives as 5-ht2a receptor ligands |
JP2002523460A (en) * | 1998-08-28 | 2002-07-30 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | Use of R-(+)-α- (2,3-dimethoxyphenyl) -1- [2- (4-fluorophenyl) ethyl] -4-piperidinemethanol for the treatment of sleep disorders |
EP1362589A1 (en) * | 1998-08-28 | 2003-11-19 | Aventis Pharmaceuticals Inc. | The use of R(+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4- piperidinemethanol for the treatment of sleep disorders |
WO2000012090A1 (en) * | 1998-08-28 | 2000-03-09 | Aventis Pharmaceuticals Inc. | THE USE OF R(+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS |
CZ301947B6 (en) * | 1998-12-16 | 2010-08-11 | Aventisub Ii Inc. | Method for the production of a pharmaceutical composition exhibiting serotonin receptor antagonist activity and pharmaceutical composition exhibiting said activity |
US6455526B1 (en) * | 1998-12-16 | 2002-09-24 | Aventis Pharmaceuticals, Inc. | Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same |
AP1769A (en) * | 1998-12-16 | 2007-08-22 | Aventisub Ii Inc | Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same. |
KR100707710B1 (en) * | 1998-12-16 | 2007-04-18 | 아벤티스 파마슈티칼스 인크. | Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same |
WO2000035423A1 (en) * | 1998-12-16 | 2000-06-22 | Aventis Pharmaceuticals Inc. | Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same |
WO2000037068A1 (en) * | 1998-12-22 | 2000-06-29 | Sanofi-Synthelabo | Use of a 5ht2a and 5ht2a/c receptor antagonist for preparing medicines for treating snoring and high resistance syndrome of upper anatomical airways |
US6576670B1 (en) | 1998-12-22 | 2003-06-10 | Sanofi—Synthelabo | Use of a 5HT2A and 5HT2A/C receptor antagonist for treating snoring and high resistance syndrome of upper anatomical airways |
US6559166B1 (en) | 1999-01-19 | 2003-05-06 | Merck Sharp & Dohme Ltd. | Phenylsulphonyl derivatives as 5-HT receptor ligands |
KR100737718B1 (en) * | 1999-07-16 | 2007-07-11 | 아벤티스 파마슈티칼스 인크. | Sulfuric acid mono-[3-?1-[2-4-fluoro-phenyl-ethyl]-piperidin-4-yl?-hydroxy-methyl-2-methoxy-phenyl]ester and pharmaceutical composition comprising the same |
US6756370B1 (en) | 1999-08-21 | 2004-06-29 | Merck Patent Gmbh | Piperidine alcohols |
EP1113015A1 (en) * | 1999-12-29 | 2001-07-04 | Pfizer Products Inc. | Optically active 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists |
US6852718B2 (en) | 2000-03-31 | 2005-02-08 | Merck Sharp & Dohme Ltd | Phenylsulphonylipiperazinyl derivatives as 5-HT receptor ligands |
US7345096B2 (en) | 2002-10-15 | 2008-03-18 | Wyeth | Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms |
US7365076B2 (en) | 2003-10-14 | 2008-04-29 | Wyeth | Substituted aryl cycloalkanol derivatives and methods of their use |
US7402698B2 (en) | 2003-10-14 | 2008-07-22 | Wyeth | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use |
US7550456B2 (en) | 2003-10-14 | 2009-06-23 | Wyeth | Substituted aryl cycloalkanoyl derivatives and methods of their use |
US7419980B2 (en) | 2003-10-14 | 2008-09-02 | Wyeth | Fused-aryl and heteroaryl derivatives and methods of their use |
US7491723B2 (en) | 2003-10-14 | 2009-02-17 | Wyeth | Alkanol and cycloalkanol-amine derivatives and methods of their use |
US7550485B2 (en) | 2003-10-14 | 2009-06-23 | Wyeth | Substituted N-heterocycle derivatives and methods of their use |
US7524846B2 (en) | 2003-10-14 | 2009-04-28 | Wyeth | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use |
US7531543B2 (en) | 2003-10-14 | 2009-05-12 | Wyeth | Phenylpiperazine cycloalkanol derivatives and methods of their use |
EP2343073A2 (en) | 2003-12-11 | 2011-07-13 | Sepracor Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
US7414052B2 (en) | 2004-03-30 | 2008-08-19 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
US7638512B2 (en) | 2004-03-30 | 2009-12-29 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
WO2006029182A3 (en) * | 2004-09-07 | 2006-08-17 | Jolla Inst For Molecular Medic | Use of mdl-100,907 for treatment of allergic and eosinophil mediated diseases |
WO2006029182A2 (en) * | 2004-09-07 | 2006-03-16 | The La Jolla Institute For Molecular Medicine | Use of mdl-100,907 for treatment of allergic and eosinophil mediated diseases |
EP2301625A2 (en) | 2004-09-30 | 2011-03-30 | F. Hoffmann-La Roche AG | Compositions and methods for treating cognitive disorders |
WO2009152647A1 (en) * | 2008-06-20 | 2009-12-23 | 江苏恩华药业股份有限公司 | Aralkyl piperidine derivatives and their uses as antalgic or ataractic agent |
US8501778B2 (en) | 2008-06-20 | 2013-08-06 | Nhwa Pharma. Corporation | Aralkyl piperidine derivatives and their uses as antalgic or ataractic agent |
Also Published As
Publication number | Publication date |
---|---|
HUT64745A (en) | 1994-02-28 |
HU9203779D0 (en) | 1993-03-29 |
AU7950991A (en) | 1991-12-31 |
FI95370C (en) | 1996-01-25 |
US5721249A (en) | 1998-02-24 |
AU652759B2 (en) | 1994-09-08 |
HU213271B (en) | 1997-04-28 |
US5700813A (en) | 1997-12-23 |
ATE114467T1 (en) | 1994-12-15 |
CA2083698A1 (en) | 1991-12-02 |
NO924619D0 (en) | 1992-11-30 |
DE69105501T2 (en) | 1995-04-13 |
EP0531410A1 (en) | 1993-03-17 |
EP0531410A4 (en) | 1993-05-26 |
KR930700103A (en) | 1993-03-13 |
GR3015087T3 (en) | 1995-05-31 |
US5700812A (en) | 1997-12-23 |
NO179250C (en) | 1996-09-04 |
FI925342A (en) | 1992-11-25 |
US5874445A (en) | 1999-02-23 |
FI95370B (en) | 1995-10-13 |
EP0531410B1 (en) | 1994-11-30 |
US5561144A (en) | 1996-10-01 |
DE69105501D1 (en) | 1995-01-12 |
ES2067937T3 (en) | 1995-04-01 |
KR100211713B1 (en) | 1999-08-02 |
CA2083698C (en) | 1997-11-04 |
JP2869512B2 (en) | 1999-03-10 |
FI925342A0 (en) | 1992-11-25 |
NO179250B (en) | 1996-05-28 |
US5134149A (en) | 1992-07-28 |
NO924619L (en) | 1992-11-30 |
DK0531410T3 (en) | 1995-01-30 |
JPH05507482A (en) | 1993-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU652759B2 (en) | (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)- 4-piperidinemethanol | |
US5071859A (en) | N-substituted azaheterocyclic carboxylic acids and pharmaceutical uses | |
DK173764B1 (en) | 1,4-Disubstituted piperidinyl compounds and pharmaceutical compositions thereof | |
EP0637306B1 (en) | 4-imidomethyl-1- [2'-phenyl-2'-oxoethyl]- piperidines as serotonin 5ht 2-antagonists, their preparation and use in therapy | |
US6004980A (en) | (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | |
AU635098B2 (en) | 1,4-disubsituted piperidinyl compounds as antithrombotic agents | |
US5292752A (en) | Antithrombotic compounds | |
CA2347469C (en) | Esters of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 100,907 | |
HU210540A9 (en) | (+)-alfa-(2,3-dimethoxyphenyl)-1-/2-(4-fluorophenyl)ethyl/-4-piperidinemethanol | |
US20040176413A1 (en) | Serotonin antagonists | |
BG65206B1 (en) | Esters of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI HU JP KR NO |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2083698 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 925342 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991910548 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1991910548 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1991910548 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 925342 Country of ref document: FI |